SCHEMBL25933767

SCHEMBL25933767

CCC(O)c1cc(C(=O)O)ccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5B Q9UGL1 10/20 0.49
KDM4C Q9H3R0 8/20 0.49
KDM5A P29375 8/20 0.49
KDM5C P41229 5/20 0.49
KDM6B O15054 4/20 0.49
KDM4A O75164 4/20 0.49
KDM4E B2RXH2 3/20 0.49
KDM2A Q9Y2K7 3/20 0.49
KDM3A Q9Y4C1 3/20 0.49
KDM4D Q6B0I6 3/20 0.49
TET3 O43151 1/20 0.49
BBOX1 O75936 1/20 0.49
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49
ASPH Q12797 1/20 0.49
TET2 Q6N021 1/20 0.49
ALKBH5 Q6P6C2 1/20 0.49
KDM7A Q6ZMT4 1/20 0.49
KDM8 Q8N371 1/20 0.49
TET1 Q8NFU7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16054683 0.85 KDM4C (0.50) KDM5BKDM4CKDM5AKDM5CKDM6B
SCHEMBL24213992 0.83 KDM4E (0.51) KDM5BKDM4CKDM5AKDM5CKDM6B
SCHEMBL14836839 0.82 KDM4C (0.47) KDM5BKDM4CKDM5AKDM5CKDM6B
SCHEMBL25933765 0.81 KDM4C (0.53) KDM5BKDM4CKDM5AKDM5CKDM6B
SCHEMBL23583774 0.80 KDM4C (0.57) KDM5BKDM4CKDM5AKDM5CKDM6B
SCHEMBL1759894 0.79 KDM4C (0.55) KDM5BKDM4CKDM5AKDM5CKDM6B
SCHEMBL5358458 0.78 KDM4C (0.46) KDM5BKDM4CKDM5AKDM5CKDM6B
SCHEMBL19705976 0.78 KDM4C (0.46) KDM5BKDM4CKDM5AKDM5CKDM6B
SCHEMBL17545205 0.77 GABRP (0.56) KDM5BKDM4CKDM5AKDM5CKDM6B
SCHEMBL25709497 0.76 KDM4C (0.52) KDM5BKDM4CKDM5AKDM5CKDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed
WO-2022015977-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2022-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 KDM5B 3550/4885KDM4C 4120/4885KDM5A 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.